Kelly L. Sullivan, PhD


Assistant Professor
Department of Epidemiology
Jiann-Ping Hsu College of Public Health
Bishop Field House, 1332 Southern Dr
Statesboro, GA 30458, USA

Biography

Dr. Sullivan is an Assistant Professor in the Department of Epidemiology at the Georgia Southern University Jiann-Ping Hsu College of Public Health. She earned her MSPH and PhD in Epidemiology at the University of South Florida.

Research Interest

Her research interest includes: Focuses on neurology, clinical epidemiology and epidemiologic methods; Parkinsons disease and movement disorders and how lifestyle and environmental factors influence health risks and outcomes.

Scientific Activities

HONORS AND AWARDS

• (2004) MDS International Travel Grant, Movement Disorder Society
• (2007-2008) Public Health Traineeship,University of South Florida

MEMBERSHIPS

• (2001-Present) Society for Epidemiologic Research
• (2003-Present) American Academy of Neurology (AAN)
• (2003-Present) Movement Disorder Society (MDS)
• (2006-Present) AAN Movement Disorders Section
• (2006-Present) AAN Neuroepidemiology Section
• (2012-Present) World Federation of Neurology, Neuroepidemiology section
• (2013-Present) European Society of Translational Medicine

Publications

1. Zesiewicz TA, Carter SN, Sullivan KL, Staffetti JF, Dunne PB, Hauser RA. Initial Management of Parkinsons Disease in a Florida Community. The Journal of Applied Research. 2004; 4: 95-98.
2. Sullivan KL, Hauser RA, Zesiewicz TA. Essential Tremor: A Review. The Neurologist. 2004, 10(5):250-258.
3. Zesiewicz TA, Strom JA, Borenstein AR, et al. Heart Failure in Parkinsons Disease: Analysis of the United States Medicare Current Beneficiary Survey. Parkinsonism & Related Disorders. 2004;10(7):417-420. doi: 10.1016/j.parkreldis.2004.04.001
4. Zesiewicz TA, Louis ED, Sullivan KL, Menkin M, Dunne PB, Hauser RA. Substantial Improvement in a Meiges Syndrome Patient with Levetiracetam Treatment. Mov Disord. 2004;19:1518-1521. doi: 10.1002/mds.20233
5. Zesiewicz TA, Stamey W, Sullivan KL, Hauser RA. Botulinum Toxin A for the Treatment of Cervical Dystonia. Current Opinon in Neurology. 2004, 5(9):2017-2024. doi: 10.1517/14656566.5.9.2017
6. Recio MV, Hauser RA, Louis ED, Radhashakar H, Sullivan KL, Zesiewicz TA. Chorea in a Cerebral Palsy Patient: Treatment with Levetiracetam. Mov Disord. 2005; 20(6):762-4. doi: 10.1002/mds.20414
7. Sullivan KL, Hauser RA, Zesiewicz TA. Levetiracetam in the Treatment of Essential Tremor. Mov Disorders. 2005; 20(5): 640. doi: 10.1002/mds.20437
8. Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA. Levetiracetam (Keppra) for the Treatment of Levodopa-Induced Dyskinesias in Parkinsons Disease. Mov Disord. 2005; 20(9): 1205-1209.
9. Zesiewicz TA, Elble R, Louis ED, et al. Practice Guideline: Treatment of Essential Tremor. Report by the American Academy of Neurology. Neurology. 2005; 64(12): 2008-1020.
10. Zesiewicz TA, Sanchez-Ramos J, Sullivan KL, Hauser RH. Levetiracetam-Induced Parkinsonism in a Huntingtons Disease Patient. Clinical Neuropharmacol. 2005; 28(4):188-190.
11. Sullivan KL, Hauser RA, Louis ED, Chari G, Zesiewicz TA. Case Report: Levetiracetam for the Treatment of Generalized Dystonia. Parkinsonism and Related Disorders. 2005; 11(7): 469-471. doi: 10.1016/j.parkreldis.2005.05.001
12. Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. Tegaserod (Zelnorm) for the Treatment of Constipation in Parkinsons Disease. Mov Disord. 2006; 21(1): 115-116. doi: 10.1002/mds.20666
13. Zesiewicz TA, Sullivan KL, Hauser RA. Vascular Hemichorea/Hemiballismus and Topiramate. Mov Disord. 2006;21(4):581. doi: 10.1002/mds.20745
14. Zesiewicz TA, Pathak A, Sullivan KL, Shamayev M, Hauser RA. Treatment of chorea with levetiracetam. Eur J Clin Pharmacol. 2006;62(1):87. doi: 10.1007/s00228-005-0028-4
15. Wolfrath SC, Borenstein AR, Schwartz S, Hauser RA, Sullivan KL, Zesiewicz TA. Use of Nutritional Supplements in Parkinsons Disease Patients. Mov Disord. 2006; 21(8): 1098-1101. doi: 10.1002/mds.20902
16. Zesiewicz TA, Sullivan KL, Hauser RA. Chorea induced by Lamotrigine. Journal of Child Neurology. 2006; 21(4): 357.
17. Zesiewicz TA, Wecker L, Sullivan KL, Merlin LR, Hauser RA. The Controversy Concerning Plasma Homocysteine in Parkinsons Disease Patients Treated with Levodopa alone or with Entacapone: Effects of Vitamin Status. Journal of Clinical Neuropharmacology. 2006 May-Jun;29(3):106-11.
18. Zesiewicz TA, Tullidge A, Tidwell J, Sullivan KL, Hauser RA. Topiramate-Induced Psychosis in Essential Tremor Patients: Report of 2 Cases. Journal of Clinical Neuropharmacology. 2006; 29(3): 168-169.
19. Zesiewicz TA, Sullivan KL, Hauser RA, Sanchez-Ramos J. An Open-Label Pilot Study of Levetiracetam (Keppra) for the Treatment of Chorea in Huntingtons Disease. Mov Disord. 2006;21(11):1998-2001. doi: 10.1002/mds.21061
20. Sullivan KL, Ward CL, Zesiewicz TA. Zonisamide-Induced Mania in an Essential Tremor Patient. Journal of Clinical Psychopharmacology. 2006; 26(4): 439-440.
21. Zesiewicz TA, Ward CL, Hauser RA, Pease Campbell JA, Sullivan KL. Pregabalin (Lyrica) in the Treatment of Essential Tremor. Movement Disorders. 2007; 22(1): 139-141. doi: 10.1002/mds.21211
22. Zesiewicz TA, Ward CL, Hauser RA, Sanchez-Ramos J, Staffetti JF, Sullivan KL. A Double-blind, Placebo-Controlled Trial of Zonisamide (Zonegran) in the Treatment of Essential Tremor. Movement Disorders. 2007; 22(2): 279-282. doi: 10.1002/mds.21282
23. Sullivan KL, Ward CL, Hauser RA, Zesiewicz TA. Prevalence and Treatment of Non-Motor Symptoms in Parkinsons Disease. Parkinsonism Relat Disord. 2007; 13(8): 545.
24. Zesiewicz TA, Sullivan KL, Hauser RA. Non-motor symptoms in Parkinsons disease. Expert Rev Neurother. 2006; 6(12): 1811-1822. doi: 10.1111/j.1468-1331.2008.02056.x
25. Zesiewicz TA, Patel-Larson A, Hauser RA, Sullivan KL. Social Security Disability Insurance (SSDI) in Parkinsons Disease. Disabil Rehabil. 2007; 29(24): 1934-1936. doi: 10.1080/09638280701257247
26. Zesiewicz TA, Sullivan KL, Ward CL, Hauser RA. Tiagabine and Exacerbation of Essential Tremor. Mov Disord. 2007; 22(14): 2132-2133. doi: 10.1002/mds.21559
27. Zesiewicz TA, Sullivan KL, Hauser RA. Levodopa-induced Dyskinesia in Parkinsons Disease: Epidemiology, Etiology, and Treatment. Curr Neurol Neurosci Rep. 2007; 7(4):302-10.
28. Zesiewicz TA, Sullivan KL, Benes LM, Smith SA, Ward CL, Hauser RA. Delayed Thalamic Intracranial Hemorrhage in an Essential Tremor Patient following Deep Brain Stimulation. Eur Neurol. 2008; 59(3-4): 187-189. doi: 10.1159/000114041
29. Zesiewicz TA, Ward CL, Hauser RA, et al. A Double-blind, Placebo-Controlled Trial of Pregabalin (Lyrica®) in the Treatment of Essential Tremor. Mov Disord. 2007; 22(11): 1660-1663. doi: 10.1002/mds.21629
30. Zesiewicz TA, Shimberg WR, Hauser RA, Robinson W, Wilson MC, Sullivan KL. Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome type 1. Clinical Rheumatology. 2008; 27(3): 389-390. doi: 10.1007/s10067-007-0744-5
31. Shimberg WR, Patel NB, Sullivan KL, Hauser RA, Zesiewicz TA. Levetiracetam for Stiff-Person Syndrome: Report of 2 Patients. Clinical Neuropharmacology. 2008; 31(5):301-2. doi: 10.1097/WNF.0b013e31815f8df0.
32. Goetz CG, Tilley BC, Shaftman SR. et al. Movement Disorder Society-Sponsored Revision of the Unified Parkinsons Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders. 2008;23(15) 2129 – 2170. doi: 10.1002/mds.22340.
33. Zesiewicz TA, Hauser RA, Freeman A, Sullivan KL, Miller AM, Halim T. Fentanyl-Induced Bradykinesia and Rigidity in a Parkinsons Disease Patient Following Deep Brain Stimulation. Clinical Neuropharmacology. 2009; 32(1):48-50. doi: 10.1097/WNF.0b013e31817e23e3.
34. Zesiewicz TA, Sullivan KL, Freeman A, Juncos JL. Treatment of imbalance with varenicline (Chantix): report of a patient with Fragile X Tremor Ataxia Syndrome (FXTAS). Acta Neurologica Scandinavica. 2009; 119(2): 135-138. doi: 10.1111/j.1600-0404.2008.01070.x
35. Zesiewicz, TA, Sullivan KL, Gooch CL. Red flags to spot the parkinsonian variant of multiple system atrophy. Nat Clin Pract Neurol. 2008; 4(11): 596-597. doi: 10.1038/ncpneuro0881
36. Zesiewicz TA, Sullivan KL. Treatment of Ataxia and Imbalance with Varenicline (Chantix®): Report of 2 Patients with Spinocerebellar Ataxia (Types 3 and 14). Clinical Neuropharmacology. 2008; 31(6): 363-365. doi: 10.1097/WNF.0b013e31818736a9.
37. Zesiewicz TA, Sullivan KL, Gooch CL, Lynch DL. Subjective Improvement in Proprioception in Two Atypical Friedreichs Ataxia Patients Treated with Varenicline (Chantix®). Journal of Clinical Neuromuscular Disease. 2009; 10(4):191-193. doi: 10.1097/CND.0b013e3181910074
38. Saleh IA, Zesiewicz TA, Xie Y, et al. Evaluation of Humoral Immune Response in Adaptive Immunity in ALS Patients During Disease Progression. Journal of Neuroimmunology. 2009; 215:96-101. doi: 10.1016/j.jneuroim.2009.07.011.
39. Jahan I, Hauser RA, Sullivan KL, Miller A, Zesiewicz TA. Sleep disorders in Parkinsons disease. Neuropsychiatr Dis Treat. 2009;5:535-40.
40. Garbuzova-Davis S, Woods RL, Louis MK, et al. Reduction of Circulating Endothelial Cells in Peripheral Blood of ALS Patients. PLoS ONE. 5(5): e10614. doi: 10.1371/journal.pone.0010614.
41. Sanchez-Ramos J, Reimer D, Zesiewicz, TA, Sullivan KL, Nausieda P. Quantitative Tremor Analysis in Welders: Comparison with Idiopathic Parkinsons Disease and Essential Tremor. Int J Environ Res Public Health. 2011;8(5):1478-90.
42. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010; 74(11):924-31. doi: 10.1212/WNL.0b013e3181d55f24.
43. Zesiewicz TA, Chari A, Jahan I, Miller AM, Sullivan KL. Overview of essential tremor. Neuropsychiatr Dis Treat. 2010; 6: 401-408.
44. Resnick AS, Okun MS, Malapira T, et al. Sustained Medication Reduction Following Unilateral VIM Thalamic Stimulation for Essential Tremor. Tremor and Other Hyperkinetic Movements. 2012; 2. doi: 10.7916/D8ZG6QZ2
45. Zesiewicz TA, Greenstein PE, Sullivan KL, et al. A Randomized Trial of Varenicline (Chantix) for the Treatment of Spinocerebellar Ataxia Type 3. Neurology. 2012;78(8):545-550. doi: 10.1212/WNL.0b013e318247cc7a
46. Zesiewicz TA, Elble FH, Louis ED, et al. Evidence-Based Guideline Update: Treatment of Essential Tremor. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2011; 77(19):1752-1755. doi: 10.1212/WNL.0b013e318236f0fd.
47. Zesiewicz TA, Sullivan KL, Hinson V, et al.Multi-site, Double-blind, Randomized, Controlled Study of Pregabalin for Essential Tremor. Movement Disorders . 2013;28(2):249-50. doi: 10.1002/mds.25264.
48. Kip KE, Sullivan KL, Lengacher CA, et al. Brief treatment of co-occurring post-traumatic stress and depressive symptoms by use of accelerated resolution therapy. Frontiers in Psychiatry. 2013; 4(article 11):1-12. doi: 10.3389/fpsyt.2013.00011
49. Zesiewicz TA, Shaw JD, Allison KG, Staffetti JS, Okun MO, Sullivan KL. Update on Treatment of Essential Tremor. Current Treatment Options in Neurology. 2013;15(4):410-23. doi: 10.1007/s11940-013-0239-4.
50. Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. American Academy of Neurology. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013; 81(5): 463-469. doi: 10.1212/WNL.0b013e31829d86b6.
51. Lerner V, Miodownik C, Sheva B, et al. Evidence-based guideline: Treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013; 81(22): 1967.
52. Bhidayasiri R, Fahn S, Gronseth GS, Sullivan KL, Zesiewicz TA. Author response. Neurology. 2014; 82(7): 643.
53. Bhidayasiri R, Fahn S, Gronseth GS, Sullivan KL, Zesiewicz TA. Author response. Neurology. 2013; 81(22): 1967.
54. Kip KE, Rosenzweig L, Hernandez DF, et al. Randomized controlled trial of accelerated resolution therapy (ART) for symptoms of combat-related post-traumatic stress disorder (PTSD). Mil Med. 2013;178(12):1298-309. doi: 10.7205/MILMED-D-13-00298.
55. Sullivan KL, Mortimer JA, Wang W, Zesiewicz TA, Brownlee HJ, Borenstein AR. Early-Adult Life Correlates of Personality in Parkinsons Disease. Journal of Neurology Research. 2014;4(2-3):51-62.
56. Sullivan KL, Mortimer JA, Wang W, Zesiewicz TA, Brownlee HJ, Borenstein AR. Premorbid Personality and the Risk of Parkinsons Disease. Journal of Neurology Research. 2014;4(2-3):81-87. doi: 10.14740/jnr281w
57. Kip KE, Rosenzweig L, Hernandez DF, et al. Accelerated Resolution Therapy for treatment of pain secondary to symptoms of combat-related posttraumatic stress disorder. Eur J Psychotraumatol. 2014; 5. doi: 10.3402/ejpt.v5.24066.
58. Zesiewicz TA, Kim SH, Sullivan KL, et al. Treatment of Neurodegenerative Ataxias With Intravenous Immune Globulin. J Neurol Res. 2014; 4(4): 97-100. doi: 10.14740/jnr291w
59. Zesiewicz TA, Evatt M, Jahan I, et al. Randomized, Controlled Pilot Trial of Solifenacin Succinate for Overactive Bladder in Parkinsons Disease. Parkinsonism and Related Disorders. 2015; 21(5): 514-520.doi: 10.1016/j.parkreldis.2015.02.025
60. Jones TM, Shaw JD, Sullivan K, Zesiewicz TA. Treatment of cerebellar ataxia. Neurodegener Dis Manag. 2014; 4(5): 379-392. doi: 10.2217/nmt.14.27
61. Politis MD, Johnson K, Hansen AR, Sullivan KL, Zhang J. The association between arthritis and depression is intensified by excessive body weight: Findings from a US national survey, 2005-2012. Obes Res Clin Pract. 2015. doi: 10.1016/j.orcp.2015.08.013.